

# Matthew D Snape

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7435154/publications.pdf>

Version: 2024-02-01

153  
papers

17,204  
citations

66234

42  
h-index

17546

121  
g-index

156  
all docs

156  
docs citations

156  
times ranked

21609  
citing authors

#	ARTICLE	IF	CITATIONS
1	Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial. <i>Lancet, The</i> , 2022, 399, 36-49.	6.3	161
2	National rates and disparities in childhood vaccination and vaccine-preventable disease during the COVID-19 pandemic: English sentinel network retrospective database study. <i>Archives of Disease in Childhood</i> , 2022, 107, 733-739.	1.0	12
3	Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6â€“17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial. <i>Lancet, The</i> , 2022, 399, 2212-2225.	6.3	23
4	Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial. <i>Lancet Respiratory Medicine</i> , 2022, 10, 1049-1060.	5.2	24
5	Immunogenicity of a single 4CMenB vaccine booster in adolescents 11 years after childhood immunisation. <i>Vaccine</i> , 2022, 40, 4453-4463.	1.7	1
6	Impact of meningococcal ACWY conjugate vaccines on pharyngeal carriage in adolescents: evidence for herd protection from the UK MenACWY programme. <i>Clinical Microbiology and Infection</i> , 2022, 28, 1649.e1-1649.e8.	2.8	20
7	Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. <i>Lancet, The</i> , 2021, 397, 99-111.	6.3	3,887
8	Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial. <i>Lancet Infectious Diseases, The</i> , 2021, 21, 493-506.	4.6	115
9	Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. <i>Nature Medicine</i> , 2021, 27, 279-288.	15.2	265
10	T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. <i>Nature Medicine</i> , 2021, 27, 270-278.	15.2	473
11	Antibody-Dependent Natural Killer Cell Activation After Ebola Vaccination. <i>Journal of Infectious Diseases</i> , 2021, 223, 1171-1182.	1.9	22
12	Meningococcal Vaccines. , 2021, , 249-259.		0
13	Respiratory Syncytial Virus Vaccination During Pregnancy and Effects in Infants. <i>Obstetrical and Gynecological Survey</i> , 2021, 76, 10-13.	0.2	1
14	Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. <i>Lancet, The</i> , 2021, 397, 881-891.	6.3	979
15	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. <i>Lancet, The</i> , 2021, 397, 1351-1362.	6.3	540
16	Immunogenicity of the UK group B meningococcal vaccine (4CMenB) schedule against groups B and C meningococcal strains (Sched3): outcomes of a multicentre, open-label, randomised controlled trial. <i>Lancet Infectious Diseases, The</i> , 2021, 21, 688-696.	4.6	5
17	Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data. <i>Lancet, The</i> , 2021, 397, 2043-2046.	6.3	231
18	Meningococcal carriage in periods of high and low invasive meningococcal disease incidence in the UK: comparison of UKMenCar1â€“4 cross-sectional survey results. <i>Lancet Infectious Diseases, The</i> , 2021, 21, 677-687.	4.6	24

#	ARTICLE	IF	CITATIONS
19	Preventing type 1 diabetes in childhood. <i>Science</i> , 2021, 373, 506-510.	6.0	52
20	SARS-CoV-2 Variants and Vaccines. <i>New England Journal of Medicine</i> , 2021, 385, 179-186.	13.9	322
21	Distinct patterns of within-host virus populations between two subgroups of human respiratory syncytial virus. <i>Nature Communications</i> , 2021, 12, 5125.	5.8	16
22	Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. <i>Lancet, The</i> , 2021, 398, 856-869.	6.3	430
23	AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein-specific T <sub>H</sub> 1 response with a diverse TCR repertoire. <i>Science Translational Medicine</i> , 2021, 13, eabj7211.	5.8	80
24	Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. <i>Nature Medicine</i> , 2021, 27, 2032-2040.	15.2	900
25	Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). <i>Lancet, The</i> , 2021, 398, 981-990.	6.3	214
26	Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 46) randomised, controlled, phase 4 trial. <i>Lancet, The</i> , 2021, 398, 2277-2287.	6.3	83
27	Supplementation with <i>Bifidobacterium longum</i> subspecies <i>infantis</i> EVC001 for mitigation of type 1 diabetes autoimmunity: the GPPAD-SINT1A randomised controlled trial protocol. <i>BMJ Open</i> , 2021, 11, e052449.	0.8	15
28	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCoV-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. <i>Lancet, The</i> , 2021, 398, 2258-2276.	6.3	519
29	Persistent Circulation of Vaccine Serotypes and Serotype Replacement After 5 Years of Infant Immunization With 13-Valent Pneumococcal Conjugate Vaccine in the United Kingdom. <i>Journal of Infectious Diseases</i> , 2020, 221, 1361-1370.	1.9	45
30	First-in-Human Randomized Study to Assess the Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus (RSV) Vaccine Based on Chimpanzee-Adenovirus-155 Viral Vector Expressing RSV Fusion, Nucleocapsid, and Antitermination Viral Proteins in Healthy Adults. <i>Clinical Infectious Diseases</i> , 2020, 70, 2073-2081.	2.9	45
31	Respiratory Syncytial Virus Consortium in Europe (RESCEU) Birth Cohort Study: Defining the Burden of Infant Respiratory Syncytial Virus Disease in Europe. <i>Journal of Infectious Diseases</i> , 2020, 222, S606-S612.	1.9	17
32	Randomized clinical trial of DTaP5-HB-IPV-Hib vaccine administered concomitantly with meningococcal serogroup C conjugate vaccines during the primary infant series. <i>Vaccine</i> , 2020, 38, 5718-5725.	1.7	2
33	Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. <i>Lancet, The</i> , 2020, 396, 467-478.	6.3	2,080
34	Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. <i>Lancet, The</i> , 2020, 396, 1979-1993.	6.3	1,196
35	Understanding the reactogenicity of 4CMenB vaccine: Comparison of a novel and conventional method of assessing post-immunisation fever and correlation with pre-release in vitro pyrogen testing. <i>Vaccine</i> , 2020, 38, 7834-7841.	1.7	0
36	Low Sensitivity of BinaxNOW RSV in Infants. <i>Journal of Infectious Diseases</i> , 2020, 222, S640-S647.	1.9	6

#	ARTICLE	IF	CITATIONS
37	Simultaneous Viral Whole-Genome Sequencing and Differential Expression Profiling in Respiratory Syncytial Virus Infection of Infants. <i>Journal of Infectious Diseases</i> , 2020, 222, S666-S671.	1.9	11
38	Respiratory Syncytial Virus Vaccination during Pregnancy and Effects in Infants. <i>New England Journal of Medicine</i> , 2020, 383, 426-439.	13.9	265
39	Be on the TEAM™ Study (Teenagers Against Meningitis): protocol for a controlled clinical trial evaluating the impact of 4CMenB or MenB-fHbp vaccination on the pharyngeal carriage of meningococci in adolescents. <i>BMJ Open</i> , 2020, 10, e037358.	0.8	11
40	COVID-19 in children and young people. <i>Science</i> , 2020, 370, 286-288.	6.0	84
41	Immunogenicity and Reactogenicity of a Reduced Schedule of a 4-component Capsular Group B Meningococcal Vaccine: A Randomized Controlled Trial in Infants. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa143.	0.4	4
42	Global Perspectives on Immunization During Pregnancy and Priorities for Future Research and Development: An International Consensus Statement. <i>Frontiers in Immunology</i> , 2020, 11, 1282.	2.2	68
43	Ebola virus glycoprotein stimulates IL-18-dependent natural killer cell responses. <i>Journal of Clinical Investigation</i> , 2020, 130, 3936-3946.	3.9	12
44	Gene expression profiling reveals insights into infant immunological and febrile responses to group B meningococcal vaccine. <i>Molecular Systems Biology</i> , 2020, 16, e9888.	3.2	7
45	Oral insulin therapy for primary prevention of type 1 diabetes in infants with high genetic risk: the GPPAD-POInT (global platform for the prevention of autoimmune diabetes primary oral insulin trial) study protocol. <i>BMJ Open</i> , 2019, 9, e028578.	0.8	62
46	Identification of infants with increased type 1 diabetes genetic risk for enrollment into Primary Prevention Trials: GPPAD 202 study design and first results. <i>Pediatric Diabetes</i> , 2019, 20, 720-727.	1.2	31
47	Common Genetic Variations Associated with the Persistence of Immunity following Childhood Immunization. <i>Cell Reports</i> , 2019, 27, 3241-3253.e4.	2.9	26
48	Determinants of Influenza and Pertussis Vaccination Uptake in Pregnancy. <i>Pediatric Infectious Disease Journal</i> , 2019, 38, 625-630.	1.1	37
49	Safety and immunogenicity of a varicella vaccine without human serum albumin (HSA) versus a HSA-containing formulation administered in the second year of life: a phase III, double-blind, randomized study. <i>BMC Pediatrics</i> , 2019, 19, 50.	0.7	3
50	Anamnestic Immune Response and Safety of an Inactivated Quadrivalent Influenza Vaccine in Primed Versus Vaccine-Naïve Children. <i>Pediatric Infectious Disease Journal</i> , 2019, 38, 203-210.	1.1	2
51	Attitudes of Pregnant Women and Healthcare Professionals Toward Clinical Trials and Routine Implementation of Antenatal Vaccination Against Respiratory Syncytial Virus: A Multicenter Questionnaire Study. <i>Pediatric Infectious Disease Journal</i> , 2019, 38, 944-951.	1.1	24
52	Meningococcal meningitis presenting postinfant group B meningococcal immunisation. <i>Archives of Disease in Childhood</i> , 2019, 104, 924.2-924.	1.0	1
53	UKMenCar4: A cross-sectional survey of asymptomatic meningococcal carriage amongst UK adolescents at a period of low invasive meningococcal disease incidence. <i>Wellcome Open Research</i> , 2019, 4, 118.	0.9	4
54	UKMenCar4: A cross-sectional survey of asymptomatic meningococcal carriage amongst UK adolescents at a period of low invasive meningococcal disease incidence. <i>Wellcome Open Research</i> , 2019, 4, 118.	0.9	2

#	ARTICLE	IF	CITATIONS
55	Antenatal vaccination against Group B streptococcus: attitudes of pregnant women and healthcare professionals in the <sc>UK</sc> towards participation in clinical trials and routine implementation. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2018, 97, 330-340.	1.3	13
56	Prevention of vaccine-matched and mismatched influenza in children aged 6â€“35 months: a multinational randomised trial across five influenza seasons. <i>The Lancet Child and Adolescent Health</i> , 2018, 2, 338-349.	2.7	51
57	A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4-year-old healthy children in the UK. <i>Vaccine</i> , 2018, 36, 2300-2306.	1.7	12
58	Pneumococcal conjugate vaccine 13 delivered as one primary and one booster dose (1â€“+â€“1) compared with two primary doses and a booster (2â€“+â€“1) in UK infants: a multicentre, parallel group randomised controlled trial. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 171-179.	4.6	97
59	Respiratory syncytial virus seasonality and its implications on prevention strategies. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 234-244.	1.4	43
60	Differences in Immunization Site Pain in Toddlers Vaccinated With Either the 10- or the 13-Valent Pneumococcal Conjugate Vaccine. <i>Pediatric Infectious Disease Journal</i> , 2018, 37, e103-e106.	1.1	2
61	Meningococcal B Vaccine Immunogenicity in Children With Defects in Complement and Splenic Function. <i>Pediatrics</i> , 2018, 142, .	1.0	17
62	High-dimensional assessment of B-cell responses to quadrivalent meningococcal conjugate and plain polysaccharide vaccine. <i>Genome Medicine</i> , 2017, 9, 11.	3.6	15
63	Persistence of immune responses induced by Ebola virus vaccines. <i>The Lancet Global Health</i> , 2017, 5, e238-e239.	2.9	2
64	Memory B cell response to a PCV-13 booster in 3.5 year old children primed with either PCV-7 or PCV-13. <i>Vaccine</i> , 2017, 35, 2701-2708.	1.7	8
65	Immune Responses to Novel Adenovirus Type 26 and Modified Vaccinia Virus Ankaraâ€“Vectored Ebola Vaccines at 1 Year. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 1075.	3.8	67
66	Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24 months and immunogenicity of a fifth dose administered at 4 years of age-a phase 3 extension to a randomised controlled trial. <i>Vaccine</i> , 2017, 35, 395-402.	1.7	19
67	Persistence of immunity after vaccination with a capsular group B meningococcal vaccine in 3 different toddler schedules. <i>Cmaj</i> , 2017, 189, E1276-E1285.	0.9	13
68	An increase in accident and emergency presentations for adverse events following immunisation after introduction of the group B meningococcal vaccine: an observational study. <i>Archives of Disease in Childhood</i> , 2017, 102, 958-962.	1.0	29
69	Where next? The emergence of hypervirulent W meningococcus in the Netherlands. <i>Lancet Public Health</i> , The, 2017, 2, e443-e444.	4.7	2
70	Divergent Memory B Cell Responses in a Mixed Infant Pneumococcal Conjugate Vaccine Schedule. <i>Pediatric Infectious Disease Journal</i> , 2017, 36, e130-e135.	1.1	10
71	Meningococcal Vaccines. , 2017, , 215-224.		0
72	The Antibody Response Following a Booster With Either a 10- or 13-valent Pneumococcal Conjugate Vaccine in Toddlers Primed With a 13-valent Pneumococcal Conjugate Vaccine in Early Infancy. <i>Pediatric Infectious Disease Journal</i> , 2016, 35, 787-793.	1.1	14

#	ARTICLE	IF	CITATIONS
73	Attitudes towards antenatal vaccination, Group B streptococcus and participation in clinical trials: Insights from focus groups and interviews of parents and healthcare professionals. <i>Vaccine</i> , 2016, 34, 4056-4061.	1.7	12
74	Control of invasive meningococcal disease. <i>International Journal of Evidence-Based Healthcare</i> , 2016, 14, 3-14.	0.1	10
75	Lymphocyte subpopulations in premature infants: an observational study. <i>Archives of Disease in Childhood: Fetal and Neonatal Edition</i> , 2016, 101, F546-F551.	1.4	4
76	Factors influencing women's attitudes towards antenatal vaccines, group B <i>Streptococcus</i> and clinical trial participation in pregnancy: an online survey. <i>BMJ Open</i> , 2016, 6, e010790.	0.8	34
77	Use of a booster dose of capsular group C meningococcal glycoconjugate vaccine to demonstrate immunologic memory in children primed with one or two vaccine doses in infancy. <i>Vaccine</i> , 2016, 34, 6350-6357.	1.7	0
78	Immunisation of the immunocompromised child. <i>Journal of Infection</i> , 2016, 72, S13-S22.	1.7	15
79	Persistence of Bactericidal Antibodies After Infant Serogroup B Meningococcal Immunization and Booster Dose Response at 12, 18 or 24 Months of Age. <i>Pediatric Infectious Disease Journal</i> , 2016, 35, e113-e123.	1.1	27
80	Safety and Immunogenicity of Novel Adenovirus Type 26 and Modified Vaccinia Ankara Vectors Vectored Ebola Vaccines. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 1610.	3.8	266
81	Sex-dependent immune responses to infant vaccination: an individual participant data meta-analysis of antibody and memory B cells. <i>Vaccine</i> , 2016, 34, 1657-1664.	1.7	38
82	Antibody Persistence and Booster Responses to Split-Virion H5N1 Avian Influenza Vaccine in Young and Elderly Adults. <i>PLoS ONE</i> , 2016, 11, e0165384.	1.1	2
83	Factors affecting the causality assessment of adverse events following immunisation in paediatric clinical trials: An online survey. <i>Vaccine</i> , 2015, 33, 7203-7210.	1.7	0
84	Immunological effect of administration of sequential doses of Haemophilus influenzae type b and pneumococcal conjugate vaccines in the same versus alternating limbs in the routine infant immunisation schedule: an open-label randomised controlled trial. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 172-180.	4.6	9
85	Understanding paratyphoid infection: study protocol for the development of a human model of Salmonella enterica serovar Paratyphi A challenge in healthy adult volunteers. <i>BMJ Open</i> , 2015, 5, e007481-e007481.	0.8	16
86	Immunogenicity of reduced dose priming schedules of serogroup C meningococcal conjugate vaccine followed by booster at 12 months in infants: open label randomised controlled trial. <i>BMJ</i> , The, 2015, 350, h1554-h1554.	3.0	27
87	Persistence of specific bactericidal antibodies at 5 years of age after vaccination against serogroup B meningococcus in infancy and at 40 months. <i>Cmaj</i> , 2015, 187, E215-E223.	0.9	29
88	Comparison of two-dose priming plus 9-month booster with a standard three-dose priming schedule for a ten-valent pneumococcal conjugate vaccine in Nepalese infants: a randomised, controlled, open-label, non-inferiority trial. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 405-414.	4.6	22
89	A Cross-Sectional Observational Study of Pneumococcal Carriage in Children, Their Parents, and Older Adults Following the Introduction of the 7-Valent Pneumococcal Conjugate Vaccine. <i>Medicine (United States)</i> , 2015, 94, e335.	0.4	24
90	Meningococcal carriage in adolescents in the United Kingdom to inform timing of an adolescent vaccination strategy. <i>Journal of Infection</i> , 2015, 71, 43-52.	1.7	61

#	ARTICLE	IF	CITATIONS
91	Neuronal Antibodies in Children with or without Narcolepsy following H1N1-AS03 Vaccination. PLoS ONE, 2015, 10, e0129555.	1.1	17
92	Will booster doses be required for serogroup B meningococcal vaccine?. Expert Review of Vaccines, 2014, 13, 313-315.	2.0	7
93	Persistence of Bactericidal Antibodies to 5 Years of Age After Immunization With Serogroup B Meningococcal Vaccines at 6, 8, 12 and 40 Months of Age. Pediatric Infectious Disease Journal, 2014, 33, 760-766.	1.1	34
94	Attitudes towards vaccination against group B streptococcus in pregnancy. Archives of Disease in Childhood, 2014, 99, 700-701.	1.0	13
95	Randomized Clinical Trial To Evaluate the Immunogenicity of Quadrivalent Meningococcal Conjugate and Polysaccharide Vaccines in Adults in the United Kingdom. Vaccine Journal, 2014, 21, 1164-1168.	3.2	12
96	Administration of AS03B-adjuvanted A(H1N1)pdm09 Vaccine in Children Aged <3 Years Enhances Antibody Response to H3 and B Viruses Following a Single Dose of Trivalent Vaccine One Year Later. Clinical Infectious Diseases, 2014, 58, 181-187.	2.9	9
97	Pandemic influenza A H1N1 vaccines and narcolepsy: vaccine safety surveillance in action. Lancet Infectious Diseases, The, 2014, 14, 227-238.	4.6	78
98	Exonic single nucleotide polymorphisms within TLR3 associated with infant responses to serogroup C meningococcal conjugate vaccine. Vaccine, 2014, 32, 3424-3430.	1.7	3
99	Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial. Lancet, The, 2014, 384, 2123-2131.	6.3	247
100	Interventions for increasing the uptake of immunisation in healthcare workers. The Cochrane Library, 2014, , .	1.5	0
101	Pneumococcal Serotype-Specific Antibodies Persist through Early Childhood after Infant Immunization: Follow-Up from a Randomized Controlled Trial. PLoS ONE, 2014, 9, e91413.	1.1	12
102	Evaluation of the Induction of Immune Memory following Infant Immunisation with Serogroup C Neisseria meningitidis Conjugate Vaccines – Exploratory Analyses within a Randomised Controlled Trial. PLoS ONE, 2014, 9, e101672.	1.1	11
103	The B-cell response to a primary and booster course of MenACWY-CRM197 vaccine administered at 2, 4 and 12 months of age. Vaccine, 2013, 31, 2441-2448.	1.7	16
104	A multicomponent serogroup B meningococcal vaccine is licensed for use in Europe: what do we know, and what are we yet to learn?. Expert Review of Vaccines, 2013, 12, 837-858.	2.0	53
105	The beginning of the end for serogroup B meningococcus?. Lancet, The, 2013, 381, 785-787.	6.3	11
106	Genetic material should be routinely collected in clinical vaccine trials – High consent rates can be achieved across all age groups. Vaccine, 2013, 31, 2744-2748.	1.7	1
107	Immune response to 13-valent pneumococcal conjugate vaccine with a reduced dosing schedule. Vaccine, 2013, 31, 4765-4774.	1.7	16
108	The price of prevention: what now for immunisation against meningococcus B?. Lancet, The, 2013, 382, 369-370.	6.3	32

#	ARTICLE	IF	CITATIONS
109	UK vaccination schedule: persistence of immunity to hepatitis B in children vaccinated after perinatal exposure. <i>Archives of Disease in Childhood</i> , 2013, 98, 429-433.	1.0	8
110	Long-term seroprotection after an adolescent booster meningococcal serogroup C vaccination. <i>Archives of Disease in Childhood</i> , 2013, 98, 686-691.	1.0	23
111	Adolescents need a booster of serogroup C meningococcal vaccine to protect them and maintain population control of the disease. <i>Archives of Disease in Childhood</i> , 2013, 98, 248-251.	1.0	18
112	Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose. <i>Cmaj</i> , 2013, 185, E715-E724.	0.9	68
113	Seroprevalence and Placental Transmission of Maternal Antibodies Specific for <i>Neisseria meningitidis</i> Serogroups A, C, Y and W135 and Influence of Maternal Antibodies on the Immune Response to a Primary Course of MenACWY-CRM Vaccine in the United Kingdom. <i>Pediatric Infectious Disease Journal</i> , 2013, 32, 768-776.	1.1	15
114	Bactericidal Antibody Persistence 2 Years After Immunization With 2 Investigational Serogroup B Meningococcal Vaccines at 6, 8 and 12 Months and Immunogenicity of Preschool Booster Doses. <i>Pediatric Infectious Disease Journal</i> , 2013, 32, 1116-1121.	1.1	38
115	Phase II Study of a Three-dose Primary Vaccination Course of DTPa-IPV/Hib-MenC-TT Followed by a 12-month Hib-MenC-TT Booster in Healthy Infants. <i>Pediatric Infectious Disease Journal</i> , 2013, 32, 675-681.	1.1	5
116	Single Nucleotide Polymorphisms in the Toll-Like Receptor 3 and CD44 Genes Are Associated with Persistence of Vaccine-Induced Immunity to the Serogroup C Meningococcal Conjugate Vaccine. <i>Vaccine Journal</i> , 2012, 19, 295-303.	3.2	17
117	Immunogenicity and Tolerability of Recombinant Serogroup B Meningococcal Vaccine Administered With or Without Routine Infant Vaccinations According to Different Immunization Schedules. <i>JAMA - Journal of the American Medical Association</i> , 2012, 307, 573-82.	3.8	247
118	H1N1 Antibody Persistence 1 Year After Immunization With an Adjuvanted or Whole-Virion Pandemic Vaccine and Immunogenicity and Reactogenicity of Subsequent Seasonal Influenza Vaccine: A Multicenter Follow-on Study. <i>Clinical Infectious Diseases</i> , 2012, 54, 661-669.	2.9	24
119	T-Cell Responses in Children to Internal Influenza Antigens, 1 Year After Immunization With Pandemic H1N1 Influenza Vaccine, and Response to Revaccination With Seasonal Trivalent "inactivated Influenza Vaccine. <i>Pediatric Infectious Disease Journal</i> , 2012, 31, e86-e91.	1.1	23
120	Antipyretic use after infant immunization. <i>Practice Nursing</i> , 2012, 23, 183-186.	0.1	0
121	The challenge of post-implementation surveillance for novel meningococcal vaccines. <i>Vaccine</i> , 2012, 30, B67-B72.	1.7	25
122	Persistence of the immune response at 5 years of age following infant immunisation with investigational quadrivalent MenACWY conjugate vaccine formulations. <i>Vaccine</i> , 2012, 30, 2831-2838.	1.7	29
123	Baseline polysaccharide-specific antibodies may not consistently inhibit booster antibody responses in infants to a serogroup C meningococcal protein polysaccharide conjugate vaccine. <i>Vaccine</i> , 2012, 30, 4153-4159.	1.7	4
124	Persistence of Antibody Response Following a Booster Dose of Hib-MenC-TT Glycoconjugate Vaccine to Five Years. <i>Pediatric Infectious Disease Journal</i> , 2012, 31, 1069-1073.	1.1	12
125	Predictors of immune response and reactogenicity to AS03B-adjuvanted split virion and non-adjuvanted whole virion H1N1 (2009) pandemic influenza vaccines. <i>Vaccine</i> , 2011, 29, 7913-7919.	1.7	35
126	Fine with five? Shorter antibiotic courses for childhood meningitis. <i>Lancet</i> , The, 2011, 377, 1809-1810.	6.3	4



#	ARTICLE	IF	CITATIONS
127	Persistence of Serum Bactericidal Antibody One Year After a Booster Dose of Either a Glycoconjugate or a Plain Polysaccharide Vaccine Against Serogroup C <i>Neisseria meningitidis</i> Given to Adolescents Previously Immunized With a Glycoconjugate Vaccine. <i>Pediatric Infectious Disease Journal</i> , 2011, 30, e203-e208.	1.1	13
128	Persistence of Immunity Following a Booster Dose of <i>Haemophilus Influenzae</i> Type B-Meningococcal Serogroup C Glycoconjugate Vaccine. <i>Pediatric Infectious Disease Journal</i> , 2011, 30, 197-202.	1.1	28
129	Immunisation of adolescents in the UK. <i>Archives of Disease in Childhood</i> , 2011, 96, 492-495.	1.0	5
130	A combination recombinant protein and outer membrane vesicle vaccine against serogroup B meningococcal disease. <i>Expert Review of Vaccines</i> , 2011, 10, 575-588.	2.0	35
131	Maintenance of Immune Response throughout Childhood following Serogroup C Meningococcal Conjugate Vaccination in Early Childhood. <i>Vaccine Journal</i> , 2011, 18, 2038-2042.	3.2	24
132	Correction: The Magnitude of the Antibody and Memory B Cell Responses during Priming with a Protein-Polysaccharide Conjugate Vaccine in Human Infants Is Associated with the Persistence of Antibody and the Intensity of Booster Response. <i>Journal of Immunology</i> , 2011, 186, 6064-6064.	0.4	0
133	Immunogenicity and Reactogenicity of a 13-Valent-pneumococcal Conjugate Vaccine Administered at 2, 4, and 12 Months of Age. <i>Pediatric Infectious Disease Journal</i> , 2010, 29, e80-e90.	1.1	114
134	Multicenter, Open-Label, Randomized Phase II Controlled Trial of an Investigational Recombinant Meningococcal Serogroup B Vaccine With and Without Outer Membrane Vesicles, Administered in Infancy. <i>Clinical Infectious Diseases</i> , 2010, 51, 1127-1137.	2.9	235
135	Immunogenicity of Two Investigational Serogroup B Meningococcal Vaccines in the First Year of Life. <i>Pediatric Infectious Disease Journal</i> , 2010, 29, e71-e79.	1.1	151
136	Plasma and memory B-cell kinetics in infants following a primary schedule of CRM <sub>197</sub> -conjugated serogroup C meningococcal polysaccharide vaccine. <i>Immunology</i> , 2009, 127, 134-143.	2.0	37
137	Humoral and cellular immune responses to split-virion H5N1 influenza vaccine in young and elderly adults. <i>Vaccine</i> , 2009, 27, 6918-6925.	1.7	20
138	Demonstration of Immunologic Memory Using Serogroup C Meningococcal Glycoconjugate Vaccine. <i>Pediatric Infectious Disease Journal</i> , 2009, 28, 92-97.	1.1	8
139	Immunogenicity and Immune Memory of a Nonadjuvanted Quadrivalent Meningococcal Glycoconjugate Vaccine in Infants. <i>Pediatric Infectious Disease Journal</i> , 2009, 28, 186-193.	1.1	58
140	Appearance of peripheral blood plasma cells and memory B cells in a primary and secondary immune response in humans. <i>Blood</i> , 2009, 114, 4998-5002.	0.6	107
141	Expediting clinical trials in a pandemic. <i>BMJ: British Medical Journal</i> , 2009, 339, b4652-b4652.	2.4	6
142	A novel combined Hib-MenC-TT glycoconjugate vaccine as a booster dose for toddlers: a phase 3 open randomised controlled trial. <i>Archives of Disease in Childhood</i> , 2008, 93, 963-970.	1.0	41
143	Immunogenicity of a Tetravalent Meningococcal Glycoconjugate Vaccine in Infants. <i>JAMA - Journal of the American Medical Association</i> , 2008, 299, 173-84.	3.8	194
144	The Magnitude of the Antibody and Memory B Cell Responses during Priming with a Protein-Polysaccharide Conjugate Vaccine in Human Infants Is Associated with the Persistence of Antibody and the Intensity of Booster Response. <i>Journal of Immunology</i> , 2008, 180, 2165-2173.	0.4	101

#	ARTICLE	IF	CITATIONS
145	Vaccines for the Prevention of Admission to the Pediatric Intensive Care Unit. , 2008, , 143-175.		0
146	A New Combination Haemophilus influenzae Type B and Neisseria meningitidis Serogroup C-Tetanus Toxoid Conjugate Vaccine for Primary Immunization of Infants. Pediatric Infectious Disease Journal, 2007, 26, 1057-1059.	1.1	33
147	African tick bite fever. Lancet Infectious Diseases, The, 2006, 6, 750.	4.6	3
148	Serogroup C Meningococcal Glycoconjugate Vaccine in Adolescents: Persistence of Bactericidal Antibodies and Kinetics of the Immune Response to a Booster Vaccine More Than 3 Years after Immunization. Clinical Infectious Diseases, 2006, 43, 1387-1394.	2.9	77
149	Lack of Serum Bactericidal Activity in Preschool Children Two Years After a Single Dose of Serogroup C Meningococcal Polysaccharide-Protein Conjugate Vaccine. Pediatric Infectious Disease Journal, 2005, 24, 128-131.	1.1	91
150	Meningococcal polysaccharideâ€“protein conjugate vaccines. Lancet Infectious Diseases, The, 2005, 5, 21-30.	4.6	163
151	Sleeping Sickness in Brothers in London. Pediatric Infectious Disease Journal, 2004, 23, 879-881.	1.1	14
152	Weight loss and purpura. Lancet, The, 1999, 354, 1352.	6.3	0
153	Single Dose&nbsp;Administration,&nbsp;And&nbsp;The&nbsp;Influence Of&nbsp;The&nbsp;Timing Of&nbsp;The&nbsp;Booster Dose&nbsp;On Immunogenicity and Efficacy Of&nbsp;ChAdOx1 nCoV-19&nbsp;(AZD1222)&nbsp;Vaccine. SSRN Electronic Journal. 0, . . .	0.4	10